Paterna Bioscience Disrupts Male Infertility Market with Capita3 Investment
Deal News | Mar 15, 2025 | Capita3 Management LLC
Capita3 Management LLC has invested in Paterna Bioscience, a biotech company focused on male infertility within the broader $20 billion infertility market. Paterna's approach targets the under-served area of male infertility, which accounts for approximately 50% of all infertility cases and where there is currently no FDA-approved treatment available. The company's proprietary solutions aim to address 1.5 million failed IVF cycles annually. Spearheaded by CEO Dr. Alex Pastuszak, Paterna's team comprises experts in urology, cancer research, and biotechnology, including Jim Hotaling, MD as CMO and Brad Cairns, PhD as Chair of Scientific Advisors. The investment from Capita3 is positioned to support Paterna's growth and market presence as it seeks to make breakthroughs in male reproductive health.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- United States – Paterna Bioscience is based in Salt Lake City, Utah, and the CEO and other key personnel are associated with the University of Utah.
Industry
- Biotechnology – The article discusses advancements in the treatment of male infertility, a segment of biotech focused on reproductive health.
- Healthcare – Paterna Bioscience operates within the healthcare sector, specifically targeting conditions related to infertility and reproductive medicine.
- Private Equity – Capita3 Management LLC's investment highlights activity within the private equity sector, providing capital for growth and development.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Capita3 Management LLC | Investor | Company | A private equity firm investing in Paterna Bioscience to support its growth in the male infertility market. |
| Paterna Bioscience | Target | Company | A biotech company focused on developing solutions for male infertility. |
| Dr. Alex Pastuszak | CEO | Person | CEO of Paterna Bioscience, with a background in academic medicine and entrepreneurship. |
| Meredith Vadis | COO | Person | COO of Paterna Bioscience, with previous experience at Vault Health. |
| Jim Hotaling, MD | CMO | Person | Chief Medical Officer at Paterna Bioscience, with expertise in urology. |
| Brad Cairns, PhD | Chair of Scientific Advisors | Person | Leading expert in chromatin and sperm biology, professor at the University of Utah. |